Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for Abvc Biopharma (ABVC) over the last 10 years, with Q3 2025 value amounting to $5821.0.

  • Abvc Biopharma's Depreciation & Amortization (CF) fell 1699.7% to $5821.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $29959.0, marking a year-over-year increase of 264.85%. This contributed to the annual value of $32025.0 for FY2024, which is 1224.63% up from last year.
  • As of Q3 2025, Abvc Biopharma's Depreciation & Amortization (CF) stood at $5821.0, which was down 1699.7% from $6697.0 recorded in Q2 2025.
  • Abvc Biopharma's Depreciation & Amortization (CF)'s 5-year high stood at $13305.0 during Q2 2024, with a 5-year trough of $1286.0 in Q1 2024.
  • In the last 5 years, Abvc Biopharma's Depreciation & Amortization (CF) had a median value of $6462.0 in 2022 and averaged $6099.3.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first tumbled by 8019.41% in 2024, then soared by 44595.65% in 2025.
  • Abvc Biopharma's Depreciation & Amortization (CF) (Quarter) stood at $3268.0 in 2021, then skyrocketed by 96.91% to $6435.0 in 2022, then increased by 17.82% to $7582.0 in 2023, then surged by 37.43% to $10420.0 in 2024, then tumbled by 44.14% to $5821.0 in 2025.
  • Its last three reported values are $5821.0 in Q3 2025, $6697.0 for Q2 2025, and $7021.0 during Q1 2025.